AstraZeneca invests $2 billion in Summit Therapeutics
STAT reports the companies are teaming up to test ivonescimab, a PD-1/VEGF bispecific drug, alongside AstraZeneca’s antibody-drug conjugates.
TLDR
STAT reports AstraZeneca is investing $2 billion in Summit Therapeutics. The companies plan to test ivonescimab alongside AstraZeneca’s antibody-drug conjugates.
Combined views
1.2K
1 Source, first seen 3h ago
1 likes